Why Is Small Cell Lung Cancer So Hard To Detect?

That nuance on how SCLC starts and spreads means that by the time most patients know something is wrong, the cancer has often already moved beyond the lung.

Diagnosing Small Cell Lung Cancer

Unlike other cancers that form slow-growing masses, small cell lung cancer specifically originates in the neuroendocrine cells of the lung, which divide quickly and can circulate through the bloodstream early on. These tumors can double in size in just 25 to 30 days, according to studies published in Lung Cancer and Journal of Thoracic Oncology — it is considered a fast growing tumor type.

But the main concern is that SCLC is quiet. The lungs themselves have no pain nerves, so tumors can grow unnoticed until they start to obstruct the airways or spread to areas like the chest wall (where there are pain nerves), liver, or brain, where symptoms appear suddenly and often severely. “So just by the nature of where it’s coming from, it leads to a late diagnosis and from that on it can rapidly progress and cause serious trouble,” Dr. Halmos says.

Common first signs of SCLC include:

• Persistent cough
• Shortness of breath
• Hoarseness
• Unexplained weight loss
• Bone pain

Unfortunately, these signs typically appear after the disease has already advanced. More than 70% of patients are diagnosed at the extensive stage, meaning it has spread beyond the chest, according to the American Cancer Society (ACS).

Because small cell lung cancer grows and spreads so fast, every step of diagnosis and treatment must move quickly. In a matter of weeks, a tumor can grow.

“Starting treatment quickly is critical,” Dr. Halmos says. “We certainly want to make sure, as treatment teams, to put patients through the diagnostic pathways as quickly as possible.”

That sense of urgency comes from experience. Without treatment, the median survival for advanced SCLC can be as short as two to four months. Fortunately, with modern chemotherapy, radiation, and immunotherapy, survival extends, averaging from 12 to 18 months for extensive-stage disease and 20 to 24 months for earlier-stage cases. Early stage disease, known as Limited Stage Small Cell Lung Cancer with treatment has a 5- year overall survival of around 25-35%.

The difference between starting treatment now versus several weeks later can directly affect outcomes. Studies show that delays longer than 30 days between diagnosis and therapy start are associated with worse survival in rapidly progressing cancers like SCLC.

Roadblocks To Early Detection

For many people, SCLC isn’t discovered because of symptoms, it’s found incidentally, during imaging for something else. A scan for pneumonia, a cardiac test, or even a routine exams for another reason might reveal the lesion.

Unfortunately, screening programs that have successfully caught early non-small cell lung cancers (like low-dose scans for heavy smokers) are less likely to catch SCLC early, because the disease tends to develop and spread in the intervals between annual scans.

This “window problem” means that even in patients who qualify for regular lung cancer screening, SCLC may appear and advance between visits. It underscores why any new respiratory symptom in a person with a smoking history should be investigated quickly, not postponed until the next scheduled scan.

Promising Future Directions

Current U.S. Preventive Services Task Force (USPSTF) criteria for low-dose CT screening focus only on age and smoking history. To qualify for screening, patients need to be between the ages of 50 and 80 and have a fairly extensive smoking history. But large population analyses show that this approach misses many SCLC cases, which often develop in slightly younger or heavier smokers who fall just outside those rules.

Researchers are now racing to close the early-detection gap in SCLC. Several major studies are moving beyond the traditional yearly low-dose CT scan, and are testing risk-model-based screening that combines age, smoking history, and other personal factors to pinpoint who is truly at highest risk.

At the same time, blood-based “liquid biopsies” are showing promise: new assays can detect fragments of tumor DNA or methylation patterns in the blood months before symptoms appear. Early data from groups at Johns Hopkins and Dana-Farber suggest these methods can identify up to 70 to 80% of early SCLC cases in pilot studies, potentially transforming how doctors find the disease, hopefully in the near future.

Other teams are taking this further by combining CT scans with biomarker tests or studying sputum and airway samples for the genetic mutations (like TP53 and RB1) that typically drive SCLC. Large projects such as TRACERx-SCLC and SUMMIT are tracking high-risk smokers to see whether these markers can flag cancer before it becomes visible on scans.

The hope is that within the next few years, screening will shift from a once-a-year picture of the lungs to a more dynamic, personalized system that catches aggressive cancers like SCLC at a stage when they can still be cured.

Questions To Ask Your Doctor

• Am I a candidate for lung cancer screening?
• What symptoms should I be aware of?
• How can I advocate for myself if I believe I need lung cancer screening?

Learn more about SurvivorNet's rigorous medical review process.

---